Andes Biotechnologies Overview
- Year Founded
-
2008
- Status
-
Out of Business
- Employees
-
3
- Latest Deal Type
-
Out of Business
Andes Biotechnologies General Information
Description
Developer of novel therapeutics intended to create a new class of drugs for the treatment of cancer. The company's therapeutics use antisense technologies to target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis, thereby enabling physicians to selectively destroy cancer cells without affecting normal cells.
Contact Information
Website
www.andesbio.comCorporate Office
- Parque Tecnológico Zañartu
- Av. Zañartu, Ñuñoa
- Santiago, 1482
- Chile
Corporate Office
- Parque Tecnológico Zañartu
- Av. Zañartu, Ñuñoa
- Santiago, 1482
- Chile
Andes Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Out of Business | 20-Dec-2020 | Completed | Out of Business | |||
| 6. Later Stage VC | 01-Jun-2018 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series B) | 15-Apr-2015 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 10-Mar-2014 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 10-May-2012 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 19-May-2011 | $4M | $4M | Completed | Generating Revenue | |
| 1. Grant | 11-Jan-2011 | Completed | Startup |
Andes Biotechnologies Patents
Andes Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2017508467-A | Pharmaceutical composition comprising rna for treating cancer and use thereof | Inactive | 14-Mar-2014 | ||
| CA-2939860-A1 | Pharmaceutical compositions comprising rna and use for treating cancer | Inactive | 14-Mar-2014 | ||
| EP-3116513-A2 | Pharmaceutical compositions comprising rna and use for treating cancer | Inactive | 14-Mar-2014 | ||
| EP-3116513-A4 | Pharmaceutical compositions comprising rna and use for treating cancer | Inactive | 14-Mar-2014 | ||
| US-20170183650-A1 | Pharmaceutical compositions comprising rna and use for treating cancer | Inactive | 14-Mar-2014 | C12N15/113 |
Andes Biotechnologies Signals
Andes Biotechnologies FAQs
-
When was Andes Biotechnologies founded?
Andes Biotechnologies was founded in 2008.
-
Where is Andes Biotechnologies headquartered?
Andes Biotechnologies is headquartered in Santiago, Chile.
-
What is the size of Andes Biotechnologies?
Andes Biotechnologies has 3 total employees.
-
What industry is Andes Biotechnologies in?
Andes Biotechnologies’s primary industry is Drug Discovery.
-
Is Andes Biotechnologies a private or public company?
Andes Biotechnologies is a Private company.
-
What is Andes Biotechnologies’s current revenue?
The current revenue for Andes Biotechnologies is .
-
How much funding has Andes Biotechnologies raised over time?
Andes Biotechnologies has raised $28M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process